Erratum: Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes (Diabetes Care (2014) 37 (3333–3335) DOI: 10.2337/dc14-1247);Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes

Diabetes Care

Volumn 37, Issue 12, 2014, Pages 3333-3335

  Myngheer, Nele ^a   Allegaert, Karel ^a,b   Hattersley, Andrew ^c   McDonald, Tim ^c   Kramer, Holger ^d   Ashcroft, Frances M ^d   Verhaeghe, Johan ^a   Mathieu, Chantal ^a,b   Casteels, Kristina ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOSIBAN; BETAMETHASONE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; NIFEDIPINE; ANTIDIABETIC AGENT; INWARDLY RECTIFYING POTASSIUM CHANNEL;

ADULT; ARTICLE; BREAST MILK; CASE REPORT; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG MILK LEVEL; FEMALE; GENETIC SCREENING; GESTATIONAL AGE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLYCEMIC CONTROL; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INFANT; KCNJ11 GENE; MACROSOMIA; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NEWBORN; NEWBORN DIABETES MELLITUS; PLACENTAL TRANSFER; POSTNATAL CARE; PREMATURE LABOR; PREMATURITY; CHEMICALLY INDUCED; CONGENITAL HYPERINSULINISM; DIABETES MELLITUS; FETAL MACROSOMIA; FETOMATERNAL TRANSFUSION; GENETICS; MUTATION; PREGNANCY;

ADULT; CONGENITAL HYPERINSULINISM; DIABETES MELLITUS; FEMALE; FETAL MACROSOMIA; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; MUTATION; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PREGNANCY;

EID: 84911884576     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc19-er07     Document Type: Erratum

References (14)

1. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838-1849
2. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic β-cell diabetes. Nat Clin Pract Endocrinol Metab 2008;4:200-213
3. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005;54:2503-2513
4. Pearson ER, Flechtner I, Njølstad PR, et al.; Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355:467-477
5. Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. Obstet Gynecol 2009;113:193-205
6. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000;343:1134-1138
7. Moretti ME, Rezvani M, Koren G. Safety of glyburide for gestational diabetes: a meta-analysis of pregnancy outcomes. Ann Pharmacother 2008;42:483-490
8. Klupa T, Kozek E, Nowak N, et al. The first case report of sulfonylurea use in a woman with permanent neonatal diabetes mellitus due to KCNJ11 mutation during a high-risk pregnancy. J Clin Endocrinol Metab 2010;95:3599-3604
9. Gaal Z, Klupa T, Kantor I, et al. Sulfonylurea use during entire pregnancy in diabetes because of KCNJ11 mutation: a report of two cases. Diabetes Care 2012;35:e40
10. Moors M, Massart DL. Evaluation of solid-phase extraction of basic drugs from human milk. J Pharm Biomed Anal 1991;9:129-139
11. Slingerland AS, Hattersley AT. Activating mutations in the gene encoding Kir6.2 alter fetal and postnatal growth and also cause neonatal diabetes. J Clin Endocrinol Metab 2006;91:2782-2788
12. Elliott BD, Langer O, Schenker S, Johnson RF. Insigni ficant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol 1991;165:807-812
13. Hebert MF, Ma X, Naraharisetti SB, et al.; Obstetric-Fetal Pharmacology Research Unit Network. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther 2009;85:607-614
14. Feig DS, Briggs GG, Kraemer JM, et al. Transfer of glyburide and glipizide into breast milk. Diabetes Care 2005;28:1851-1855